Abstract
Original language | English |
---|---|
Pages (from-to) | 1096-1107 |
Number of pages | 12 |
Journal | Genetics in Medicine |
Volume | 24 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1 May 2022 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
CDK13-related disorder : Report of a series of 18 previously unpublished individuals and description of an epigenetic signature. / Rouxel, Flavien; Relator, Raissa; Kerkhof, Jennifer et al.
In: Genetics in Medicine, Vol. 24, No. 5, 01.05.2022, p. 1096-1107.Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - CDK13-related disorder
T2 - Report of a series of 18 previously unpublished individuals and description of an epigenetic signature
AU - Rouxel, Flavien
AU - Relator, Raissa
AU - Kerkhof, Jennifer
AU - McConkey, Haley
AU - Levy, Michael
AU - Dias, Patricia
AU - Barat-Houari, Mouna
AU - Bednarek, Nathalie
AU - Boute, Odile
AU - Chatron, Nicolas
AU - Cherik, Florian
AU - Delahaye-Duriez, Andrée
AU - Doco-Fenzy, Martine
AU - Faivre, Laurence
AU - Gauthier, Lucas W.
AU - Heron, Delphine
AU - Hildebrand, Michael S.
AU - Lesca, Gaëtan
AU - Lespinasse, James
AU - Mazel, Benoit
AU - Menke, Leonie A.
AU - Morgan, Angela T.
AU - Pinson, Lucile
AU - Quelin, Chloe
AU - Rossi, Massimiliano
AU - Ruiz-Pallares, Nathalie
AU - Tran-Mau-Them, Frederic
AU - van Kessel, Imke N.
AU - Vincent, Marie
AU - Weber, Mathys
AU - Willems, Marjolaine
AU - Leguyader, Gwenael
AU - Sadikovic, Bekim
AU - Genevieve, David
N1 - Funding Information: Funding for this study was provided, in part, by the London Health Sciences Molecular Diagnostics Innovation and Development Fund and Genome Canada Genomic Applications Partnership Program Grant (Beyond Genomics: Assessing the Improvement in Diagnosis of Rare Diseases using Clinical Epigenomics in Canada, EpiSign-CAN) awarded to B.S. This work has been generated within the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA), [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. Funding Information: Funding for this study was provided, in part, by the London Health Sciences Molecular Diagnostics Innovation and Development Fund and Genome Canada Genomic Applications Partnership Program Grant (Beyond Genomics: Assessing the Improvement in Diagnosis of Rare Diseases using Clinical Epigenomics in Canada, EpiSign-CAN) awarded to B.S. This work has been generated within the European Reference Network on Rare Congenital Malformations and Rare Intellectual Disability (ERN-ITHACA), [EU Framework Partnership Agreement ID: 3HP-HP-FPA ERN-01-2016/739516]. We deeply thank the families for their participation in this work. We thank the European Reference Network ITHACA Congenital Malformations and Rare Intellectual Disability (https://ern-ithaca.eu) and the Anomalies du Développement Déficience Intellectuelle de causes Rares network (http://anddi-rares.org) for the diffusion of the partnership proposal. Conceptualization: D.G. B.S.; Data Curation: R.R. F.R. N.R.-P. M.B.-H. N.C.; Formal Analysis: R.R. F.R.; Funding Acquisition: B.S.; Investigation: D.G. M.We. L.P. M.Wi. F.C. J.K. H.M. P.D. N.B. O.B. A.D.-D. M.D.-F. L.F. L.G. D.H. J.L. B.M. L.A.M. I.N.V.K. A.T.M. C.Q. M.R. L.W.G.; Methodology: D.G. B.S.; Project Administration: D.G.; Supervision: D.G. B.S.; Writing-original draft: F.R. R.R. D.G. B.S.; Writing-review and editing: F.R. R.R. J.K. H.M. M.L. P.D. M.B.-H. N.B. O.B. N.C. F.C. A.D.-D. M.D.-F. L.F. L.W.G. D.H. M.S.H. G.Les. J.L. B.M. L.A.M. A.T.M. L.P. C.Q. M.R. N.R.-P. F.T.-M.-T. I.N.V.K. M.V. M.We. M.Wi. G.Leg. B.S. D.G. This study was approved by the University Hospital of Montpellier (29/05/2020; IRB-MTP_2020_05_202000466); ClinicalTrial.gov identifier: NCT04382573. Informed consent was obtained from all participants as required by the Institutional Review Board. Consent was received for the use of photos. All institutions involved in human participant research received local Institutional Review Board approval. Publisher Copyright: © 2021
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Purpose: Rare genetic variants in CDK13 are responsible for CDK13-related disorder (CDK13-RD), with main clinical features being developmental delay or intellectual disability, facial features, behavioral problems, congenital heart defect, and seizures. In this paper, we report 18 novel individuals with CDK13-RD and provide characterization of genome-wide DNA methylation. Methods: We obtained clinical phenotype and neuropsychological data for 18 and 10 individuals, respectively, and compared this series with the literature. We also compared peripheral blood DNA methylation profiles in individuals with CDK13-RD, controls, and other neurodevelopmental disorders episignatures. Finally, we developed a support vector machine–based classifier distinguishing CDK13-RD and non–CDK13-RD samples. Results: We reported health and developmental parameters, clinical data, and neuropsychological profile of individuals with CDK13-RD. Genome-wide differential methylation analysis revealed a global hypomethylated profile in individuals with CDK13-RD in a highly sensitive and specific model that could aid in reclassifying variants of uncertain significance. Conclusion: We describe the novel features such as anxiety disorder, cryptorchidism, and disrupted sleep in CDK13-RD. We define a CDK13-RD DNA methylation episignature as a diagnostic tool and a defining functional feature of the evolving clinical presentation of this disorder. We also show overlap of the CDK13 DNA methylation profile in an individual with a functionally and clinically related CCNK-related disorder.
AB - Purpose: Rare genetic variants in CDK13 are responsible for CDK13-related disorder (CDK13-RD), with main clinical features being developmental delay or intellectual disability, facial features, behavioral problems, congenital heart defect, and seizures. In this paper, we report 18 novel individuals with CDK13-RD and provide characterization of genome-wide DNA methylation. Methods: We obtained clinical phenotype and neuropsychological data for 18 and 10 individuals, respectively, and compared this series with the literature. We also compared peripheral blood DNA methylation profiles in individuals with CDK13-RD, controls, and other neurodevelopmental disorders episignatures. Finally, we developed a support vector machine–based classifier distinguishing CDK13-RD and non–CDK13-RD samples. Results: We reported health and developmental parameters, clinical data, and neuropsychological profile of individuals with CDK13-RD. Genome-wide differential methylation analysis revealed a global hypomethylated profile in individuals with CDK13-RD in a highly sensitive and specific model that could aid in reclassifying variants of uncertain significance. Conclusion: We describe the novel features such as anxiety disorder, cryptorchidism, and disrupted sleep in CDK13-RD. We define a CDK13-RD DNA methylation episignature as a diagnostic tool and a defining functional feature of the evolving clinical presentation of this disorder. We also show overlap of the CDK13 DNA methylation profile in an individual with a functionally and clinically related CCNK-related disorder.
KW - CDK13
KW - CHDFIDD
KW - Clinical
KW - Epigenetic
KW - Signature
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85122983149&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/35063350
U2 - 10.1016/j.gim.2021.12.016
DO - 10.1016/j.gim.2021.12.016
M3 - Article
C2 - 35063350
SN - 1098-3600
VL - 24
SP - 1096
EP - 1107
JO - Genetics in Medicine
JF - Genetics in Medicine
IS - 5
ER -